COSYNTROPIN
LOE ApproachingNDAINTRAVENOUSSOLUTION
Approved
Feb 2008
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 17h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Cosyntropin is a synthetic adrenocorticotropic hormone (ACTH) analog administered intravenously as a solution. It binds to adrenal cortical cell receptors to stimulate glucocorticoid production via the cAMP pathway, primarily used for diagnostic testing of adrenal function. The drug is indicated for patients requiring assessment of adrenocortical insufficiency and related endocrine disorders.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30), indicating potential team restructuring and transition planning for brand protection strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Cosyntropin Versus Epidural Blood Patch (EBP) for Treatment of Treatment of Post Dural Puncture Headache
Started Aug 2010
29 enrolled
Postdural Puncture Headache
Career Relevance
Cosyntropin represents a specialized diagnostic product with limited career growth momentum as it approaches loss of exclusivity. Professionals joining this team should expect focus on margin preservation, physician relationships, and managing competitive transition rather than market expansion.
Brand Manager
Worked on COSYNTROPIN at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.